Please select the option that best describes you:
Would you use AR-V7 testing to decide second-line androgen receptor-axis-targeted therapy vs chemotherapy for patients who with metastatic castration-resistant prostate cancer?
If yes, what factors push you to test for AR-V7 or would you test all patients in this clinical scenario?
Answer from: Medical Oncologist at Academic Institution
In our PROPHECY multicenter AR-V7 validation trial, we compared the JHU AR-V7 CTC RNA test against the Epic/Genomic Sciences nuclear protein CTC AR-V7 test. Both tests, when positive, were strongly associated with lack of PSA response, short PFS, and short OS in men with mCRPC receiving abiraterone ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Next generation AR therapy remains a critical therapy option for most patients with mCRPC. As some patients who test AR-V7 positive still respond to these agents and a psa 4-6 weeks after starting one of these drugs will provide "early" clinical information regarding response I do not use AR-V...
Comments
Medical Oncologist at Siri Onclogy and hematology Infusion Service
If one looks at the survival in an epic ARV7 + pat...
If one looks at the survival in an epic ARV7 + pat...
Answer from: Medical Oncologist at Community Practice
Yes, I use the Johns Hopkins AR-V7 test (since it is available at my institution!) in two settings. In the first-line (treatment-naive) mCRPC setting, I use the test to determine who NOT to treat initially with Abi or Enza. Only 8-10% of patients will have a positive JHU AR-V7 test in this set...